IDT Biologika provides state-of-the art process development and GMP manufacturing facilities, with the capabilities to serve as a critical translational bridge from development through clinical to commercial BSL2 manufacturing.
Our successful track record demonstrates that we can address significant challenges and fill vital development program needs of vaccine and biopharmaceutical customers applied to market. IDT has GMP compliant end-to-end equipment and operating capabilities that meet FDA, EMA and ANVISA standards. We have many years of experience with live agents and proteins and the flexibility to support most platform technologies. Our team is dedicated and cross-trained with a considerable depth and breadth of experience and expertise in third party viral and biologic manufacturing procedures. With end-to-end operational capabilities, proven product development experience and broad technology expertise, the IDT Biologika team works with partners to handle difficult and complex projects and enable the transition from early concept through clinical trials to commercial manufacturing. With a strong record of success combined with on-time, on budget delivery of challenging projects, we are confident in our ability to meet your product development needs.
clinical trial materials produced
in the last 8 years
of commercial filling of pharmaceuticals